Autoimmune signals in non-segmental vitiligo patients are associated with distinct clinical parameters and toxic exposures

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 8, 2013, Pages 961-966

  Arunachalam, M ^a   Colucci, R ^a   Berti, S ^a   Kline, J A ^b   Lotti, T ^a   Lotti, F ^a   Dragoni, F ^a   Moretti, S ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAROLINAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNITY; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CHILD; COMPARATIVE STUDY; DISEASE DURATION; DRUG EXPOSURE; DRUG TOXICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MCNEMAR TEST; MEDICAL HISTORY; ONSET AGE; PRIORITY JOURNAL; SCHOOL CHILD; SMOKING; VITILIGO;

ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; VITILIGO;

EID: 84880510409     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04614.x     Document Type: Article

References (24)

1. Ortonne JP, Moscher DB, Fitzpatrick TB,. Hypomelanotic Disorders. In:, Ortonne JP, Moscher DB, Fitzpatrick TB, eds. Vitiligo and Other Hypomelanoses of Hair and Skin. Plenum Medical Book Co., New York (NY), 1983: 129-310.
2. Gauthier Y, Cario André M, Taïeb A,. A critical appraisal of vitiligo etiologic theories: is melanocyte loss a melanocytorrhagy? Pigment Cell Res 2003; 16: 322-332.
3. Hann SK, Nordlund J, editors. Vitiligo. Blackwell Science, Oxford, 2000.
4. Howitz J, Brodthagen H, Schwartz M, Thomsen K,. Prevalence of vitiligo: epidemiological survey on the Isle of Bornholm, Denmark. Arch Dermatol 1977; 113: 47-52.
5. Boisseau-Garsaud AM, Garsaud P, Calès-Quist D, et al. Epidemiology of vitiligo in the French West Indies (Isle of Martinique). Int J Dermatol 2000; 39: 18-20.
6. Das SK, Majumder PP, Chakraborty R, et al. Studies on vitiligo. I. Epidemiological profile in Calcutta, India. Genet Epidermiol 1985; 2: 71-78.
7. Das SK, Majumder TK, Halder B,. Studies on vitiligo. II. Familial aggregation and genetics. Genet Epidemiol 1985; 2: 255-262.
8. Majumder PP, Das SK, Li CC,. A genetic model for vitiligo. Am J Hum Genet 1988; 43: 119-125.
9. Majumder PP, Nordlund JJ, Nath SK,. Pattern of familial aggregation of vitiligo. Arch Dermatol 1993; 129: 994-998.
10. Nordlund JJ, Lerner AB,. Vitiligo. It is important. Arch Dermatol 1982; 118: 5-8.
11. Koga M, Tango T,. Clinical features and course of type A and type B vitiligo. Br J Dermatol 1988; 118: 223-228.
12. Schallreuter KU, Lemke R, Brandt O,. Vitiligo and other diseases: coexistence or true association? Dermatology 1994; 188: 269-275.
13. Ingordo V, Gentile C, Iannazzone SS, et al. Vitiligo and autoimmunity: an epidemiological study in a representative sample of young Italian males. J Eur Acad Dermatol Venereol 2011; 25: 105-109.
14. Taieb A, Picardo on behalf of VETF members. The Definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 2007; 20: 27-35.
15. Alkhateeb A, Fain PR, Thody A, et al. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 2003; 16: 208-214.
16. Onunu AN, Kubeyinje EP,. Vitiligo in Nigerian African: a study of 351 patients in Benin City, Nigeria. Int J Dermatol 2003; 42: 800-802.
17. Linthorst Homan MW, Spuls PI, de Korte J, et al. The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol 2009; 61: 411-420.
18. Daneshpazhooh M, Mostofizadeh GM, Behjati J, et al. Anti-thyroid peroxidase antibody and vitiligo. A controlled study BMC Dermatol 2006; 6: 3.
19. EffrAISidis G, Tijssen J, Wiersinga WM,. Discontinuation of smoking increases the risk for developing thyroid peroxidase antibodies and/or thyroglobulin antibodies: a prospective study. J Clin Endocrinol Metab 2009; 94: 1324-1328.
20. Laberge G, Mailloux CM, Gowan K, et al. Early disease onset and increased risk of other autoimmune diseases in famil generalized vitiligo. Pigment Cell Res 2005; 18: 300-305.
21. Ongenae K, Van Geel N, Naeyaert JM,. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003; 16: 90-100.
22. Runello F, Garofalo M.R., Sicurella C, et al. Il gozzo nodulare. Caleidoscopio 2006; 35: 3-45.
23. Chang C, Gershwin ME,. Drugs and autoimmunity-a contemporary review and mechanistic approach. J Autoimmun 2010; 34: J266-1275.
24. Guerra L, Dellambra E, Brescia S, Raskovic D,. Vitiligo: pathogenetic hypotheses and targets for current therapies. Curr Drug Metab 2010; 11: 451-467.